• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Sex Differences in Liver Disease Remodeling Follow Shared Directional Pathways

by
November 13, 2026
in Health
Reading Time: 8 mins read
0
Sex Differences in Liver Disease Remodeling Follow Shared Directional Pathways

Sex Differences in Liver Disease Remodeling Follow Shared Directional Pathways

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A fully in silico transcriptomic investigation published in the Egyptian Liver Journal has revealed that sex-dependent molecular divergence across metabolic dysfunction-associated steatotic liver disease stems from distinct pathway architecture, continuous disease severity coupling, and baseline expression shifts rather than inverted gene-expression directions. Led by researcher Tunahan Anber, the study systematically profiled sex-stratified hepatic gene expression across human liver biopsy datasets to clarify how biological sex influences the progression from healthy liver tissue through simple steatosis to metabolic dysfunction-associated steatohepatitis. By analyzing discovery profiles from the Gene Expression Omnibus alongside targeted assessments in two independent validation series, the author tested whether sex-biased disease signatures reflect opposing transcriptional programs or nuanced differences in the magnitude, timing, and biological modules engaged during chronic hepatic injury. The resulting computational analysis establishes that men and women share core directional pathways during progressive liver injury while deploying distinct sets of genes within those pathways, offering a refined framework for interpreting immuno-metabolic heterogeneity across the clinical spectrum of metabolic dysfunction-associated steatotic liver disease.

Understanding biological sex as a fundamental source of heterogeneity in steatotic liver disease has gained urgency following the recent multi-society Delphi consensus nomenclature transition. This formal update replaced older nonalcoholic fatty liver disease terms with metabolic dysfunction-associated steatotic liver disease to eliminate non-inclusive terminology and directly anchor disease definitions to cardiometabolic risk parameters, while preserving steatohepatitis as a central pathophysiological category. Epidemiological evidence shows that metabolic liver disease exhibits clear sex-dimorphic patterns, presenting with a higher overall prevalence in men than in premenopausal women, whereas disease prevalence rises sharply in women following menopause, who are also overrepresented among cohorts with advanced fibrosis. These differences are widely believed to be driven by immuno-metabolic crosstalk, adipose tissue distribution, sex hormone signaling, and sex-biased innate immune activation that alter the transition from benign lipid accumulation to inflammatory hepatic injury. Although high-throughput liver transcriptomics has repeatedly connected disease progression to shifts in immune activation, cellular stress responses, and extracellular matrix remodeling, prior profiling efforts rarely positioned biological sex as a primary stratification parameter across defined stages, leaving significant uncertainty regarding which molecular signatures are sex-specific, shared, or reproducible.

To establish a controlled discovery framework, the investigation examined microarrays from Gene Expression Omnibus series GSE89632, generated from human liver biopsies profiled on the Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip platform under accession GPL14951. The discovery cohort comprised sixty-three liver biopsy transcriptomes distributed across six sex-stratified diagnostic groups, including thirteen female controls, six females with simple steatosis, ten females with metabolic dysfunction-associated steatohepatitis, eleven male controls, fourteen males with simple steatosis, and nine males with steatohepatitis. Alongside expression profiles, clinical and histological parameters curated from repository metadata included age, body mass index, diabetes status, aspartate aminotransferase, alanine aminotransferase, and histological scores encompassing steatosis, lobular inflammation, hepatocellular ballooning, fibrosis stage, and the composite NAFLD Activity Score. Notably, descriptive baseline summaries illustrated clinical variability among subgroups: mean body mass index was 26.20 kilograms per square meter in female controls and 25.51 in male controls, increasing to 32.45 in female steatohepatitis and 31.11 in male steatohepatitis, while median NAFLD Activity Scores rose from zero in both control groups to 5.0 in female steatohepatitis and 4.0 in male steatohepatitis. The female simple steatosis group was clinically distinct, characterized by an older mean age of 51.2 years and a high diabetes prevalence of 66.7 percent.

Differential expression analysis was executed through GEO2R using linear models with empirical Bayes moderation, setting uniform thresholds of absolute log2 fold change of at least one and Benjamini-Hochberg adjusted p-values of 0.05 or less. The four diagnostic contrasts evaluated were female simple steatosis versus female control, female steatohepatitis versus female control, male simple steatosis versus male control, and male steatohepatitis versus male control. These comparisons demonstrated that transcriptomic remodeling varied substantially according to sex and disease stage under the applied cutoffs. In females, simple steatosis relative to control yielded 486 significantly upregulated and 575 downregulated features, while the female steatohepatitis contrast identified 211 upregulated and 367 downregulated features. Conversely, males displayed an inverse progression dynamic: male simple steatosis produced 217 upregulated and 310 downregulated features, whereas male steatohepatitis showed a dramatic expansion in transcriptional disruption, revealing 522 upregulated and 576 downregulated features. Consequently, the greatest differential expression burden across all evaluated comparisons appeared in males experiencing advanced steatohepatitis, highlighting stage-dependent remodeling differences between sexes.

To explore overall regulatory architecture beyond individual contrasts, the author aggregated significant probe sets within each sex across steatosis and steatohepatitis to conduct Venn-based set comparisons of directional responses. When comparing same-direction signatures, substantial overlap emerged alongside prominent sex-specific components. Among upregulated features, 245 genes were shared by both sexes, while 340 genes were unique to females and 312 genes were unique to males, establishing total upregulated signatures of 585 female genes and 557 male genes. Downregulated profiles demonstrated a similar pattern: 340 features were shared across sexes, alongside 313 female-specific and 265 male-specific genes, representing overall downregulated signatures of 653 and 605 genes, respectively. Crucially, cross-directional comparisons revealed zero overlapping genes between the female-downregulated and male-upregulated sets, as well as zero overlap between the female-upregulated and male-downregulated sets. This complete absence of opposing directional regulation confirms that sex differences in liver transcriptomes do not reflect broad transcriptional reversals where one sex upregulates a gene while the other suppresses it. Instead, sex differences operate through shared directional programs characterized by distinct, sex-specific gene membership within those common pathways.

Functional enrichment analyses conducted through Enrichr on sex-aggregated gene sets using Reactome Pathways and Gene Ontology Biological Process databases resolved the biological themes underlying these sex-specific signatures. In Reactome analysis, female-specific upregulated genes were heavily enriched for chromatin organization, nucleosome assembly, centromere-associated processes, chromosome maintenance, cell cycle regulation, and DNA repair, outlining a transcriptional program oriented around genome stability, chromatin remodeling, and cellular proliferation. In sharp contrast, male-specific upregulated genes mapped predominantly to interferon signaling, interferon alpha and beta signaling, and antiviral responses associated with oligoadenylate synthetase pathways, reflecting pronounced innate immune activation. Female-specific downregulated features were enriched for extracellular matrix organization, extracellular proteoglycans, elastic fiber pathways, cytokine signaling, and hemostasis, indicating coordinated suppression of structural matrix-remodeling programs under the selected cutoffs. The male-specific downregulated set yielded no significant enrichment in Reactome. Parallel Gene Ontology biological process evaluations mirrored these exact patterns, confirming male-biased interferon and antiviral activation alongside female-biased chromatin, cell-cycle, and matrix-associated remodeling programs.

Guided by these functional enrichment patterns and established disease biology, the researcher curated a focused panel of nineteen candidate genes grouped into five thematic modules: a female-downregulated innate immune and apoptosis module containing BCL2L11, KDM6B, METRNL, TLR2, and TNIP3; a female-upregulated chromatin and cell-cycle module comprising BACH2, BAZ1A, KNL1, and PHC2; a female-upregulated inflammasome module with ACE2 and CASP1; a male-upregulated interferon module featuring CCL7, GBP5, OAS1, and OAS2; and a metabolic anchor module spanning LEPR, NNMT, P4HA1, and PNPLA3. When tested using two-way analysis of variance with diagnosis and sex as fixed factors, diagnosis emerged as the dominant categorical contributor across all nineteen genes, yielding nominal significance with p-values of 0.0007 or lower. Following Benjamini-Hochberg false discovery rate correction within the sex main effect family at an FDR threshold below 0.10, only BCL2L11 retained a significant sex effect, with an unadjusted p-value of 0.0012 and a q-value of 0.0228. P4HA1 showed a nominal sex effect of p equal to 0.0458 that touched the discovery boundary at a q-value of 0.10, whereas no sex-by-diagnosis interaction survived false discovery rate correction across the entire panel.

Because clinical imbalances could confound categorical observations, complete-case sensitivity analyses were executed incorporating age, body mass index, and diabetes status across sixty-one discovery samples with complete clinical records. Following multivariable covariate adjustment using Type III sum-to-zero contrasts, no categorical sex main effect or sex-by-diagnosis interaction retained false discovery rate support at a q-value below 0.10. Nominal main effects for sex persisted only for BCL2L11 and ACE2, while METRNL and GBP5 retained nominal interaction terms. This attenuation demonstrated that categorical gene-level sex differences were highly sensitive to underlying clinical covariate structures, especially given the small female simple steatosis sample size. However, shifting from categorical groupings to continuous modeling against the histological NAFLD Activity Score revealed much stronger, resilient sex-dependent associations. When modeling continuous disease severity against the NAFLD Activity Score, patatin-like phospholipase domain containing 3, or PNPLA3, demonstrated a significant sex difference in regression slopes with a steeper positive induction in males, an effect that successfully maintained statistical support after multivariable adjustment for age, body mass index, and diabetes status with an interaction p-value of 0.0073 and a q-value of 0.0219.

Continuous regression modeling also clarified the behavior of prolyl 4-hydroxylase subunit alpha 1, P4HA1, and the leptin receptor, LEPR. Unlike PNPLA3, neither P4HA1 nor LEPR displayed significant sex differences in their regression slopes across increasing NAFLD Activity Scores, indicating that their rates of change across disease severity were comparable between sexes. Instead, both genes exhibited significant intercept differences, reflecting higher fitted baseline expression in females across the histological activity continuum. In unadjusted models, the female-higher intercept difference for P4HA1 achieved significance with a p-value of 0.0033 and a q-value of 0.0528, while LEPR showed an intercept p-value of 0.0070 and a q-value of 0.0560. Following multivariable adjustment, the female-higher baseline expression difference for LEPR remained robust with a p-value of 0.0384 and a q-value of 0.0576, whereas the P4HA1 signal was attenuated to a non-significant q-value of 0.1047. In contrast, parallel regression models testing associations against hepatic arachidonic acid, measured as a percentage of total liver lipids, showed no sex-dependent differences in slopes or intercepts for any lead gene after multiple-testing correction, confirming that continuous sex coupling in these transcripts was specific to histological disease activity rather than overall hepatic polyunsaturated fatty acid composition.

The distinction between histological activity and lipid exposure was further reinforced by clean sex-stratified Pearson correlation heatmaps constructed across all nineteen candidate genes, displaying only associations surviving a Benjamini-Hochberg false discovery rate below 0.10. For the NAFLD Activity Score, the correlation architecture was sharply polarized between sexes: females exhibited fourteen supported correlations dominated by broad negative associations across the female-downregulated and chromatin modules, including BCL2L11, KDM6B, METRNL, TLR2, TNIP3, BACH2, BAZ1A, LEPR, NNMT, and P4HA1, with positive correlations limited to KNL1, ACE2, CASP1, and OAS1. In contrast, males displayed ten supported correlations characterized by positive associations with interferon and metabolic genes, including OAS1, OAS2, GBP5, ACE2, CASP1, KNL1, and PNPLA3, with PNPLA3 achieving significance exclusively in males. When evaluated against hepatic arachidonic acid, the correlation structure became remarkably broad and shared, encompassing sixteen genes in females and eighteen genes in males. Both sexes shared persistent positive correlations between arachidonic acid and BCL2L11, KDM6B, METRNL, TLR2, TNIP3, BACH2, BAZ1A, CCL7, LEPR, NNMT, and P4HA1, while displaying negative correlations with KNL1, ACE2, and CASP1, illustrating that arachidonic acid aligns with widespread metabolic transcription across both sexes while disease activity isolates sex-polarized programs.

To evaluate cross-cohort reproducibility, the four lead genes—BCL2L11, PNPLA3, P4HA1, and LEPR—were examined in two independent Gene Expression Omnibus cohorts, revealing partial, phenotype-dependent concordance. The cohorts possessed significant demographic differences: mean age was 41.59 years in discovery series GSE89632, compared to 50.56 years in GSE130970 and 54.06 years in GSE167523, while body mass index and diabetes prevalence were significantly elevated in GSE130970. In the RNA-sequencing cohort GSE130970, which permitted continuous NAFLD Activity Score regression, LEPR provided the strongest replication, displaying significantly higher overall female expression with a p-value of 0.0002 and a significant regression intercept difference of p equal to 0.000115 without a slope difference, replicating the female-higher baseline pattern. P4HA1 demonstrated higher overall female expression with a p-value of 0.0206, though its regression intercept difference missed significance. PNPLA3 showed a non-significant directional trend toward a steeper male slope with p equal to 0.0665, while BCL2L11 showed no sex-associated signals. In the categorical RNA-sequencing cohort GSE167523, comparing nonalcoholic fatty liver and steatohepatitis, PNPLA3 demonstrated a significant sex-by-diagnosis interaction with a p-value of 0.0300, confirming sex-dependent disease association across differing diagnostic frameworks, whereas LEPR was associated solely with disease stage and BCL2L11 and P4HA1 showed no sex effects.

The study highlights essential methodological considerations and limitations inherent to secondary computational analyses of public functional genomics repositories. The small size of the female simple steatosis discovery group restricted statistical power for detecting subtle categorical interaction terms, and critical biological modifiers such as menopausal status, hormone replacement therapy, precise alcohol thresholds, medication histories, and PNPLA3 genotypes could not be accounted for directly. Furthermore, technical differences between discovery microarrays and validation RNA-sequencing platforms, divergent diagnostic categorization schemes, and clinical demographic disparities across cohorts explain why individual statistical parameters showed partial rather than uniform cross-cohort replication. Finally, because transcriptomic data were derived from bulk liver tissue, the observed signatures reflect aggregate tissue signals rather than cell-type-specific profiles, meaning that male interferon enrichment or female extracellular matrix shifts cannot be definitively mapped to specific cellular compartments such as hepatocytes, hepatic stellate cells, Kupffer cells, or infiltrating immune populations. Nevertheless, these findings demonstrate that sex differences in metabolic dysfunction-associated steatotic liver disease are effectively captured through continuous severity coupling and pathway architecture rather than categorical inversion, establishing clear molecular hypotheses for future prospective studies.

Subject of Research: Sex-stratified hepatic transcriptomic remodeling and severity coupling across metabolic dysfunction-associated steatotic liver disease

Article Title: Sex-dependent baseline expression and severity coupling define key transcriptomic differences across MASLD

Article References: Anber, T. (2026). Sex-dependent baseline expression and severity coupling define key transcriptomic differences across MASLD. Egyptian Liver Journal, 16(1), Article 60. https://doi.org/10.1186/s43066-026-00540-5

Image Credits: AI Generated

DOI: 10.1186/s43066-026-00540-5

Keywords: MASLD, MASH, Liver Transcriptomics, Sex Differences, PNPLA3, LEPR, P4HA1, BCL2L11, NAFLD Activity Score, Arachidonic Acid, GSE89632, GSE130970, GSE167523, Gene Expression Omnibus, Interferon Signaling, Extracellular Matrix, Functional Genomics, Hepatic Steatosis

News Source: Juliet Wilcox. (November 13, 2026). Sex Differences in Liver Disease Remodeling Follow Shared Directional Pathways. Scienmag.

Tags: arachidonic acidBCL2L11extracellular matrixFunctional genomicsGene Expression OmnibusGSE130970GSE167523GSE89632hepatic steatosisinterferon signalingLEPRLiver TranscriptomicsMASHMASLDNAFLD Activity ScoreP4HA1PNPLA3sex differences
Share12Tweet7Share2ShareShareShare1

Related Posts

Non-Invasive Intracranial Waveform Monitoring Shows High Negative Predictive Value for Emergency CT

Non-Invasive Intracranial Waveform Monitoring Shows High Negative Predictive Value for Emergency CT

November 16, 2026
Pediatric Eosinophilic Gastrointestinal Disorders Link to Inborn Errors of Immunity

Pediatric Eosinophilic Gastrointestinal Disorders Link to Inborn Errors of Immunity

November 16, 2026

Retinal Vascular Loss Precedes Neuronal Thinning in Early Multiple Sclerosis

November 16, 2026

Study Finds Clinically Meaningful Discordance in Myasthenia Gravis Patient-Physician Pairs

November 16, 2026

POPULAR NEWS

  • New Hangingfly Species Discovered in Mozambique Features Rare Hind Leg Structure

    New Hangingfly Species Discovered in Mozambique Features Rare Hind Leg Structure

    29 shares
    Share 12 Tweet 7
  • Psychiatric Diagnosis Faces New Risks in the Age of AI

    29 shares
    Share 12 Tweet 7
  • Fig Leaf Silver Nanoparticles Eliminate Cattle Ticks in Laboratory Bioassays

    29 shares
    Share 12 Tweet 7
  • South Korean Whipworms Lack Classic Resistance Mutations in Full-Length Genetic Study

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Non-Invasive Intracranial Waveform Monitoring Shows High Negative Predictive Value for Emergency CT

Pediatric Eosinophilic Gastrointestinal Disorders Link to Inborn Errors of Immunity

Maize Gene Disruption Enhances Salt-Alkaline Tolerance and Confers Male Sterility

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.